This test is most useful if any of these apply to you.
If your knuckles are swollen and stiff each morning but your first arthritis blood tests were negative, anti-MCV may add useful information. It detects antibodies associated with rheumatoid arthritis, including some cases missed by anti-CCP and rheumatoid factor. Its added value varies across studies, and persistent joint swelling still needs an examination even when all three tests are negative.
Anti-MCV is a second-line diagnostic marker with published evidence linking it to joint damage. Its usefulness for choosing treatment, tracking flares, or screening people without symptoms is less established than its association with rheumatoid arthritis.
Vimentin is a structural protein inside many types of cells. Citrullination changes one of a protein's building blocks from arginine to citrulline. This process occurs in normal biology as well as inflammation, including inflammation in joints.
Some people's immune systems make antibodies that recognize altered vimentin. Anti-MCV testing detects their reaction to a modified, citrullinated form of that protein. Anti-CCP testing uses short protein fragments made in a laboratory that contain citrulline. The targets overlap enough that results often agree, but they aren't identical.
Published accuracy estimates mainly come from serum obtained through a blood draw. Serum is the liquid left after blood clots. Results are reported in units per milliliter (U/mL). The scale depends on the laboratory's assay, so results from different methods cannot be assumed to be interchangeable.
Anti-MCV can support a diagnosis when your symptoms and joint examination suggest rheumatoid arthritis. It is usually considered after, or alongside, rheumatoid factor and anti-CCP. Anti-CCP generally has greater specificity, so it produces fewer positive results in people with other diseases.
Sensitivity describes how often a test detects people who have the disease. Specificity describes how often it stays negative in people who don't. Neither percentage is the chance that you personally have rheumatoid arthritis after a positive result. That depends on your symptoms, examination, other results, and how likely the disease was before testing.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| A review of 33 studies with 6,044 people with rheumatoid arthritis and 5,094 healthy or disease controls | The analysis using people with other diseases as controls | Anti-MCV was positive in about 71% of rheumatoid arthritis cases and negative in about 89% of disease controls; anti-CCP had similar detection with fewer false positives |
| 170 people with early rheumatoid arthritis and 136 controls | Early rheumatoid arthritis versus other diseases and healthy people | Anti-MCV was positive in about 78% of early cases and negative in about 93% of controls |
| 326 people assessed through a reference laboratory, plus 50 healthy controls | Anti-MCV versus anti-CCP, rheumatoid factor, and 14-3-3 eta | Anti-MCV had 71% sensitivity and 92% specificity; anti-CCP had higher sensitivity with the same reported specificity |
A negative result leaves rheumatoid arthritis possible. A positive result is more persuasive when you have persistent joint swelling than when you feel well and tested because of family history alone.
In one study, anti-MCV was found in about 12% of people with rheumatoid arthritis who tested negative for anti-CCP. Some were also negative for rheumatoid factor. But a more recent reference-laboratory study found no additional cases among people negative for both standard antibodies. These results support selective use when the diagnosis remains uncertain; they don't establish a reliable detection rate for everyone with negative initial tests.
Seronegative rheumatoid arthritis usually refers to rheumatoid arthritis with negative rheumatoid factor and anti-CCP results. The diagnosis can still be made from the pattern of joint inflammation and other findings.
Requiring both anti-MCV and anti-CCP to be positive reduced false positives in one early rheumatoid arthritis study: about 98% of controls were negative by that combined rule. But the rule detected only about 59% of cases. Two positive antibodies strengthen diagnostic evidence without replacing the joint examination.
Anti-MCV also occurs in some people with lupus, psoriatic arthritis, and other inflammatory joint diseases. Studies have found positive results in hepatitis C and Epstein-Barr virus infection as well. The frequency depends on the population and assay.
These findings make an isolated positive result harder to interpret. They don't show that every positive during an infection is temporary, or that a persistent result confirms rheumatoid arthritis.
Some long-term studies associate anti-MCV with more joint damage. In a ten-year study that enrolled 238 people with rheumatoid arthritis, the main X-ray analysis included 125 with complete imaging. Those who were anti-MCV positive at the start had about seven times the odds of worsening X-ray damage compared with those who were negative. The estimate applied to positivity, not specifically to the highest antibody levels, and it described odds rather than a sevenfold increase in probability.
Higher levels were also associated with more progression in that study. In a separate cohort of 210 people with early rheumatoid arthritis, anti-MCV positivity was associated with more disease activity over two years. These findings can add information about future joint damage, but they don't establish a universal antibody target or a treatment decision based on this result alone.
The evidence for monitoring is less consistent. In 162 people with early arthritis followed for two years, changes in antibody levels were only weakly related to changes in disease activity. An analysis from a 52-week treatment trial found that baseline anti-MCV did not independently predict treatment response or X-ray progression after other factors were considered.
A single-center study of 257 people with rheumatoid arthritis reported associations between anti-MCV positivity and cardiovascular disease and interstitial lung disease. Interstitial lung disease can involve inflammation and scarring of lung tissue. The study was cross-sectional, so it cannot establish whether the antibody predicts future complications.
Another study of 100 people with early rheumatoid arthritis and 100 healthy controls linked anti-MCV to thicker carotid artery walls on ultrasound. That finding concerns an imaging marker, not a demonstrated ability to predict heart attacks. These studies haven't established an anti-MCV-based plan for heart or lung screening.
Anti-MCV levels sometimes fall during treatment, but the relationship with symptoms and joint inflammation is inconsistent. Serial measurements haven't been shown to improve routine treatment decisions. Joint examinations, symptoms, and standard disease-activity assessments remain the basis for judging control of rheumatoid arthritis.
Evidence-backed interventions that affect your MCV Antibody level
MCV Antibody is best interpreted alongside these tests.